Neutrophil-lymphocyte ratio as a possible prognostic marker in central nervous system tumors: an integrative literature review
DOI:
https://doi.org/10.33448/rsd-v11i11.33998Keywords:
Glioma; Glioblastoma; Prognosis; NLR.Abstract
Introduction: Gliomas are primary tumors originating in the brain parenchyma. Recent studies explore the role of some leukocytes and other markers of inflammation in clinical outcomes associated with the development and progression of this cancer, among them there is the neutrophil per lymphocyte ratio (NLR). Aim: The purpose of this study is to understand, through studies published in the literature, the quantitative neutrophil/lymphocyte ratio and its implications for the prognosis of patients. Methodology: Integrative literature review on the PubMed database of productions from the last 11 years. The descriptors used were: "glioma", "glioblastoma", "NLR", "neutrophil to lymphocyte ratio", "neutrophil lymphocyte ratio", "neutrophil-to-lymphocyte ratio", "prognostic", "prognosis" and "outcome". Results: Sixteen articles were selected at the end of the search steps. The year 2019 being the most prevalent with 31.25% of the publications, followed by the years 2017 and 2018 appearing each year with 18.75%. Regarding the countries of origin of the studies, 50% were conducted in China, followed by the studies conducted in Turkey with 25%. Therefore, it is assertive that a high NLR rate suggests a worse prognosis in patients with gliomas. This is based on two important considerations: (1) the rate varies according to the grade of the glioma, with high grade gliomas (III and IV) having in most cases higher NLR than low grade gliomas (I and II) and (2) the overall survival of individuals with low NLR is considerably higher than in those with high. Final Considerations: NLR has important value as a low-cost and reliable prognostic biomarker, however, further studies are needed seeking to obtain a common NLR cutoff point.
References
Ary, A., & Gunver, F. (2019). Comparison of neutrophil–lymphocyte ratio and platelet–lymphocyte ratio in patients with thyroiditis and papillary tumors. Journal of International Medical Research, 47(5), 2077-2083. https://doi.org/10.1177/0300060519838392
Chovanec, M., Cierna, Z., Miskovska, V., Machalekova, K., Kalavska, K., Rejlekova, K., Svetlovska, D., Macak, D., Spanik, S., Kajo, K., Babal, P., De Giorgi, U., Mego, M., & Mardiak, J. (2018). Systemic immune-inflammation index in germ-cell tumours. British Journal of Cancer, 118(6), 831-838. https://doi.org/10.1038/bjc.2017.460
Gandhi, P., Khare, R., Gulwani, H., & Kaur, S. (2018). Circulatory YKL-40 & NLR: Underestimated Prognostic Indicators in Diffuse Glioma. International Journal of Molecular and Cellular Medicine, 7(2), 111-118. https://doi.org/10.22088/IJMCM.BUMS.7.2.111
Grier, J. T., & Batchelor, T. (2006). Low-Grade Gliomas in Adults. The Oncologist, 11(6), 681-693. https://doi.org/10.1634/theoncologist.11-6-681
Haksoyler , V., Bensen , A. A., Koseci, T., Olgun, P., Bayram, E., & Topkan, E. (2021). Neutrophil-to-lymphocyte ratio is prognostic in recurrent glioblastoma multiforme treated with bevacizumab plus irinotecan. Future Medicine, 15(11), 851-859. https://doi.org/10.2217/bmm-2021-0271
Huang, Y., Ding, H., Wu, Q., Li, Z., Li, H., Li, S., Xie, C., & Zhong, Y. (2019). Neutrophil–lymphocyte ratio dynamics are useful for distinguishing between recurrence and pseudoprogression in high-grade gliomas. Dovepress, 11, 6003-6009. https://doi.org/10.2147/CMAR.S202546
Kaya, V., Yildirim, M., Yazici, G., Yalçin, A. Y., Orhan, N., & Guzel, A. (2017). Prognostic Significance of Indicators of Systemic Inflammatory Responses in Glioblastoma Patients. Asian Pacific Journal of Cancer Prevention, 18(12), 3287-3291. https://doi.org/10.22034/APJCP.2017.18.12.3287
Kemerdere, R., Akgun, M. Y., Toklu, S., Alizada, O., & Tanriverdi, T. (2019). Preoperative systemic inflammatory markers in low- and high-grade gliomas: A retrospective analysis of 171 patients. Heliyon, 5(5), 1-5. https://doi.org/10.1016/j.heliyon.2019.e01681
Ma, L., Li, G., & Wei, M. (2020). Neutrophil-to-Lymphocyte Ratio and Its Changes are Related to Grade II–IV Glioma Recurrence. Dovepress, 12, 9429-9434. https://doi.org/10.2147/CMAR.S267523
Margetts, J., Ogle, L. F., Chan, S. L., Chan, A. W. H., Chan, K. C. A., Jamieson, D., Willoughby, C. E., Mann, D. A., Wilson, C. L., Manas, D. M., Yeo, W., & Reeves, H. L. (2017). Neutrophils: driving progression and poor prognosis in hepatocellular carcinoma? British Journal of Cancer, 118(2), 248-257. https://doi.org/10.1038/bjc.2017.386
Mermut, O., & Inanc, B. (2020). The Effect of Indicators of Systemic Inflammatory Response on Survival in Glioblastoma Multiforme. Turkish Neurosurgery, 30(5), 658-665. https://doi.org/10.5137/1019-5149.JTN.27068-19.1
Ocana, A., Nieto-Jiménez, C., Pandiella, A., & Templeton, A. J. (2017). Neutrophils in cancer: prognostic role and therapeutic strategies. Molecular Cancer, 16(137), 1-7. https://doi.org/10.1186/s12943-017-0707-7
Ostrom, Q. T., Patil, N., Waite, K., Kruchko, C., & Barnholtz-Sloan, J. S. (2020). CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2013-2017. Neuro-Oncology, 22(1), iv1-iv96. https://doi.org/10.1093/neuonc/noaa200
Sharma, G., Jain, S. K., & Sinha, V. D. (2021). Peripheral Inflammatory Blood Markers in Diagnosis of Glioma and IDH Status. Thieme, 12(01), 88-94. https://doi.org/10.1055/s-0040-1721166
Siegel, R. L., Miller, K. D., Fuchs, H. E., & Jemal, A. (2021). Cancer Statistics, 2021. CA: A Cancer Journal for Clinicians, 71(1), 1-27. https://doi.org/10.3322/caac.21654
Stupp, R., Brada, M., van den Bent, M., Tonn, J., & Pentheroudakis, G. (2014). High-grade glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†. Annals of Oncology, 25(3), iii93-iii101. https://doi.org/10.1093/annonc/mdu050
Subeikshanan, V., Dutt, A., Basu, D., Tejus, M., Maurya, V., & Madhugiri, V. (2016). A prospective comparative clinical study of peripheral blood counts and indices in patients with primary brain tumors. Journal of Postgraduate Medicine, 62(2), 86-90. https://doi.org/10.4103/0022-3859.180551
The Cancer Genome Atlas Research Network. (2013). Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature, 455(506), 1061-1068. https://doi.org/10.1038/nature07385
Wang, J., Xiao, W., Chen, W., & Hu, Y. (2018). Prognostic significance of preoperative neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in patients with glioma. EXCLI Journal, 17, 505-512. https://doi.org/https://10.17179/excli2017-978
Wang, P., Meng, Z., Song, H., Yao, K., Duan, Z., Yu, C., Li, S., & Yan, C. (2018). Preoperative Changes in Hematological Markers and Predictors of Glioma Grade and Survival. Frontiers in Farmacology, 9(886), 1-7. https://doi.org/10.3389/fphar.2018.00886
Wang P., Song H., Cai H., Kong L., Yao K., Jiang T., Li S., Yan C. (2017). Preoperative inflammation markers and IDH mutation status predict glioblastoma patient survival. Oncotarget, 8(30), 50117-50123. https://doi.org/10.18632/oncotarget.15235
Wang, Z., Zhang, C., Liu, Y., Wang, Z., & Jiang, T. (2019). Peripheral blood test provides a practical method for glioma evaluation and prognosis prediction. CNS Neuroscience & Therapeutics, 25(8), 876-883. https://doi.org/10.1111/cns.13120
Wiencke, J. K., Koestler, D. C., Salas, L. A., Wiemels, J. L., Roy, R. P., Hansen, H. M., Rice, T., McCoy, L. S., Bracci, P. M., Molinaro, A. M., Kelsey, K. T., Wrensch, M. R., & Christensen, B. C. (2017). Immunomethylomic approach to explore the blood neutrophil lymphocyte ratio (NLR) in glioma survival. Clinical Epigenetics, 9(1), 10-21. https://doi.org/10.1186/s13148-017-0316-8
Yang, T., Mao, P., Chen, X., Niu, X., Xu, G., Bai, X., & Xie, W. (2018). Inflammatory biomarkers in prognostic analysis for patients with glioma and the establishment of a nomogram. Oncology Letters, 17(2), 2516-2522. https://doi.org/10.3892/ol.2018.9870
Zhang, Z., Zhan, Y., Zhang, F., Yu, B., Ji, Y., Zhou, J., Bai, Y., Wang, Y., Wang, L., Jing, Y., Duan, W., Sun, C., Sun, T., Zhao, H., Li, K., Wang, W., Li, R., Sun, H., Zhai, G., Wang, S., Wei, X., Yang, B., Yan, D., Liu, X., & Wang, W. (2019). Prognostic value of preoperative hematological markers combined with molecular pathology in patients with diffuse gliomas. Aging, 11(16), 6252-6272. https://doi.org/10.18632/aging.102186
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 Lucas Furlan Cirqueira de Souza; Paulo André de Lacerda Alves; Michel Reis Abdalla; Eduardo Elias Vieira de Carvalho; Ana Karina Marques Salge; George Kemil Abdalla; Douglas Reis Abdalla
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
